Evidence map›Paper›PMID 42894212›Full record

ArticleCancer cell international2026

ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination-proficient high-grade serous ovarian cancer.

Sijia Cheng, Jiayi Li, Yunzhi Ling, Jiaru Luo, Dan Zhou, Tianle Mao, Tingting Luo, Yanyang Tu, Jinlin Du, Minghui Zhou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sijia Cheng *Department of Gynecology, Huizhou Central People's Hospital, No. 41, E Ling North Road, Huicheng District, Huizhou, 516001, Guangdong, China.
Jiayi Li *Department of Epidemiology and Statistics, School of Public Health, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Yunzhi Ling *Science Research Center, Huizhou Central People's Hospital, Huizhou, 516001, Guangdong, China.
Jiaru LuoScience Research Center, Huizhou Central People's Hospital, Huizhou, 516001, Guangdong, China.
Dan ZhouDepartment of Gynecology, Huizhou Central People's Hospital, No. 41, E Ling North Road, Huicheng District, Huizhou, 516001, Guangdong, China.
Tianle MaoDepartment of Gynecology, Huizhou Central People's Hospital, No. 41, E Ling North Road, Huicheng District, Huizhou, 516001, Guangdong, China.
Tingting LuoScience Research Center, Huizhou Central People's Hospital, Huizhou, 516001, Guangdong, China.
Yanyang TuScience Research Center, Huizhou Central People's Hospital, Huizhou, 516001, Guangdong, China.
Jinlin DuDepartment of Epidemiology and Statistics, School of Public Health, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Minghui ZhouDepartment of Gynecology, Huizhou Central People's Hospital, No. 41, E Ling North Road, Huicheng District, Huizhou, 516001, Guangdong, China. ppa666@163.com.
Qingsong QinLaboratory of Human Virology and Oncology, Shantou University Medical College, No. 22 Xinling Road, Jinping District, Shantou, 515041, Guangdong, China. qsqin@stu.edu.cn.
Yanqin JiDepartment of Gynecology, Huizhou Central People's Hospital, No. 41, E Ling North Road, Huicheng District, Huizhou, 516001, Guangdong, China. yqjihzch@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2022A1515110197Guangdong Basic and Applied Basic Research Foundation 2023B1515120085Guangdong Basic and Applied Basic Research Foundation 2024A1515110272Huizhou Science and Technology Program 2024CZ010270Shenzhen Science and Technology Program JCYJ20220530152008019
6 · The paper itself

Abstract

backgroundPoly(ADP-ribose) polymerase (PARP) inhibitor resistance represents a major clinical challenge in both homologous recombination deficiency-positive (HRD

objectiveThis study aimed to investigate whether ACSF2 modulates PARP inhibitor resistance by regulating p53-binding protein 1 (53BP1) nuclear foci formation and to determine if ACSF2 influences histone H4 Lysine 20 di-methylation (H4K20me2)-mediated 53BP1 recruitment via KMT5B in HRD

methodsUsing machine learning, ACSF2 was identified as a key resistance gene to PARP inhibitor. This discovery was based on an integrated analysis of six platinum-sensitive recurrent ovarian cancer (OC) cell lines (HRD

resultsACSF2 was provisionally identified as key mediator of PARP inhibitor resistance, with high expression correlating with poorer median overall survival in patients (42.00 vs. 49.60 months, P < 0.05). Similarly, ACSF2 acted as a key regulator of Niraparib sensitivity. Overexpression of ACSF2 increased the IC

conclusionACSF2 promotes Niraparib resistance in HRD

Indexed as

Acyl-CoA synthetase family member 2Homologous recombination deficiency- negativeNiraparibOvarian cancerPoly(ADP-ribose) polymerase inhibitorResistance

Identifiers

PMID42894212
PMCPMC13678890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.